{"transactions":[{"id":730578,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":4,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":5,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":6,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":7,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":9,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":10,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T20:00:07.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a restricted stock unit (\"RSU\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 17, 2027 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with BP Directors, LP (\"Bios Directors\"), Dr. Fletcher has agreed that he will hold certain equity-based awards granted to him in connection with his services as a director of the Issuer merely as a nominee for Bios Directors. Bios Directors may be deemed the direct or indirect beneficial owner of the reported securities, and Bios Equity Partners, LP (\"Bios Equity I\"), Cavu Management, LP (\"Cavu Management\"), Bios Capital Management, LP (\"Bios Management\"), Cavu Advisors LLC (\"Cavu Advisors\"), Bios Advisors GP, LLC (\"Bios Advisors\"), Leslie W. Kreis, Jr. (\"Mr. Kreis\") and Dr. Fletcher may each be deemed the indirect beneficial owner of the reported securities through his or its respective indirect interest in Bios Directors."}],"balance_after":81229,"source":{"system":"sec-edgar","filing":"0001789490-26-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000178949026000002/primary_doc.xml","form_type":"4"}},{"id":1099351,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-06-30T13:02:42.000Z","date":"2025-06-27","kind":"purchase","planned":false,"acquired":true,"shares":71428,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios 2024 Co-Invest, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Warrants are exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the earliest to occur of (i) the U.S. Food and Drug Administration (\"FDA\") issuing Breakthrough Therapy designation for elraglusib and (ii) the date that the FDA provides written communication available to the Issuer of its determination as to whether the Issuer may pursue registration for elraglusib using Phase 2 or Phase 3 clinical data."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Warrants are exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the earliest to occur of (i) the U.S. Food and Drug Administration (\"FDA\") issuing Breakthrough Therapy designation for elraglusib and (ii) the date that the FDA provides written communication available to the Issuer of its determination as to whether the Issuer may pursue registration for elraglusib using Phase 2 or Phase 3 clinical data."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Warrants are exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the earliest to occur of (i) the U.S. Food and Drug Administration (\"FDA\") issuing Breakthrough Therapy designation for elraglusib and (ii) the date that the FDA provides written communication available to the Issuer of its determination as to whether the Issuer may pursue registration for elraglusib using Phase 2 or Phase 3 clinical data."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Footnote 3 Continue) Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Footnote 3 Continue)The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":71428,"derivative":{"exercise_price":7,"underlying":"Common Stock","underlying_shares":71428},"source":{"system":"sec-edgar","filing":"0001104659-25-063992","document":"tm2519406-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925063992/tm2519406-3_4seq1.xml","form_type":"4"}},{"id":1099350,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-30T13:02:42.000Z","date":"2025-06-27","kind":"purchase","planned":false,"acquired":true,"shares":71428,"price":7,"value":499996.0,"ownership":{"direct":false,"nature":"Directly held by Bios 2024 Co-Invest, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a Securities Purchase Agreement (the \"Securities Purchase Agreement\"), dated as of June 25, 2025, between Actuate Therapeutics, Inc. (the \"Issuer\") and certain institutional and accredited investors, Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\") purchased from the Issuer in a private placement 71,428 shares of common stock, par value $0.000001 per share (the \"Common Stock\"), and warrants to purchase 71,428 shares of Common Stock (the \"Warrants\"). The closing of the transactions contemplated by the Securities Purchase Agreement occurred on June 27, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Footnote 3 Continue) Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Footnote 3 Continue)The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":196428,"source":{"system":"sec-edgar","filing":"0001104659-25-063992","document":"tm2519406-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925063992/tm2519406-3_4seq1.xml","form_type":"4"}},{"id":1105083,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":4,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":5,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":6,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36364,"kind":"person","name":"BIOS Memory SPV I, LP","position":7,"cik":"0001643749","reported_name":"BIOS Memory SPV I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":9,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":10,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-20T21:38:56.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a restricted stock unit (\"RSU\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 18, 2026 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to Aaron G.L. Fletcher's (\"Dr. Fletcher\") continuous service as a director as of the applicable vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with BP Directors, LP (\"Bios Directors\"), Dr. Fletcher has agreed that he will hold certain equity-based awards granted to him in connection with his services as a director of the Issuer merely as a nominee for Bios Directors. Bios Directors may be deemed the direct or indirect beneficial owner of the reported securities, and Bios Equity Partners, LP (\"Bios Equity I\"), Cavu Management, LP (\"Cavu Management\"), Bios Capital Management, LP (\"Bios Management\"), Cavu Advisors LLC (\"Cavu Advisors\"), Bios Advisors GP, LLC (\"Bios Advisors\"), Leslie W. Kreis, Jr. (\"Mr. Kreis\") and Dr. Fletcher may each be deemed the indirect beneficial owner of the reported securities through his or its respective indirect interest in Bios Directors."}],"balance_after":48500,"source":{"system":"sec-edgar","filing":"0001104659-25-061241","document":"tm2518563-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925061241/tm2518563-1_4seq1.xml","form_type":"4"}},{"id":1111847,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T23:57:00.000Z","date":"2025-06-13","kind":"sale","planned":false,"acquired":false,"shares":4354,"price":3.09,"value":13453.86,"ownership":{"direct":false,"nature":"by Bios Fund II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 13, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.05 to $3.26, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":114272,"source":{"system":"sec-edgar","filing":"0001104659-25-059528","document":"tm2518021-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059528/tm2518021-2_4seq1.xml","form_type":"4"}},{"id":1111846,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T23:57:00.000Z","date":"2025-06-13","kind":"sale","planned":false,"acquired":false,"shares":14218,"price":3.09,"value":43933.62,"ownership":{"direct":false,"nature":"By Bios Fund II QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 13, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.05 to $3.26, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":373178,"source":{"system":"sec-edgar","filing":"0001104659-25-059528","document":"tm2518021-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059528/tm2518021-2_4seq1.xml","form_type":"4"}},{"id":1111845,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T23:57:00.000Z","date":"2025-06-13","kind":"sale","planned":false,"acquired":false,"shares":1903,"price":3.09,"value":5880.27,"ownership":{"direct":false,"nature":"By Bios Fund II NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 13, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.05 to $3.26, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":49957,"source":{"system":"sec-edgar","filing":"0001104659-25-059528","document":"tm2518021-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059528/tm2518021-2_4seq1.xml","form_type":"4"}},{"id":1111844,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T23:57:00.000Z","date":"2025-06-13","kind":"sale","planned":false,"acquired":false,"shares":12319,"price":3.09,"value":38065.71,"ownership":{"direct":false,"nature":"By Bios Fund I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 13, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.05 to $3.26, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":323335,"source":{"system":"sec-edgar","filing":"0001104659-25-059528","document":"tm2518021-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059528/tm2518021-2_4seq1.xml","form_type":"4"}},{"id":1111843,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T23:57:00.000Z","date":"2025-06-13","kind":"sale","planned":false,"acquired":false,"shares":7206,"price":3.09,"value":22266.54,"ownership":{"direct":false,"nature":"By Bios Fund I QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 13, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.05 to $3.26, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":189117,"source":{"system":"sec-edgar","filing":"0001104659-25-059528","document":"tm2518021-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059528/tm2518021-2_4seq1.xml","form_type":"4"}},{"id":1111841,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-12","kind":"sale","planned":false,"acquired":false,"shares":6601,"price":3.38,"value":22311.38,"ownership":{"direct":false,"nature":"By Bios Fund II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 12, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.57 to $3.25, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":118626,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111840,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-11","kind":"sale","planned":false,"acquired":false,"shares":103,"price":3.4,"value":350.2,"ownership":{"direct":false,"nature":"By Bios Fund II, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":125227,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111839,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-10","kind":"sale","planned":false,"acquired":false,"shares":2,"price":3.4,"value":6.8,"ownership":{"direct":false,"nature":"By Bios Fund II, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":125330,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111838,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-12","kind":"sale","planned":false,"acquired":false,"shares":21557,"price":3.38,"value":72862.66,"ownership":{"direct":false,"nature":"By Bios Fund II QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 12, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.57 to $3.25, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":387396,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111837,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-11","kind":"sale","planned":false,"acquired":false,"shares":338,"price":3.4,"value":1149.2,"ownership":{"direct":false,"nature":"By Bios Fund II QP, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":408953,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111836,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-10","kind":"sale","planned":false,"acquired":false,"shares":5,"price":3.4,"value":17.0,"ownership":{"direct":false,"nature":"By Bios Fund II QP, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":409291,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111835,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-12","kind":"sale","planned":false,"acquired":false,"shares":2886,"price":3.38,"value":9754.68,"ownership":{"direct":false,"nature":"By Bios Fund II NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 12, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.57 to $3.25, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":51860,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111834,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-11","kind":"sale","planned":false,"acquired":false,"shares":45,"price":3.4,"value":153.0,"ownership":{"direct":false,"nature":"By Bios Fund II NT, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":54746,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111833,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-10","kind":"sale","planned":false,"acquired":false,"shares":1,"price":3.4,"value":3.4,"ownership":{"direct":false,"nature":"By Bios Fund II NT, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":54791,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111832,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-12","kind":"sale","planned":false,"acquired":false,"shares":18678,"price":3.38,"value":63131.64,"ownership":{"direct":false,"nature":"By Bios Fund I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 12, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.57 to $3.25, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":335654,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111831,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-11","kind":"sale","planned":false,"acquired":false,"shares":293,"price":3.4,"value":996.2,"ownership":{"direct":false,"nature":"By Bios Fund I, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":354332,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111830,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-10","kind":"sale","planned":false,"acquired":false,"shares":5,"price":3.4,"value":17.0,"ownership":{"direct":false,"nature":"By Bios Fund I, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":354625,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111829,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-12","kind":"sale","planned":false,"acquired":false,"shares":10925,"price":3.38,"value":36926.5,"ownership":{"direct":false,"nature":"By Bios Fund I QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 12, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.57 to $3.25, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":196323,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111828,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-11","kind":"sale","planned":false,"acquired":false,"shares":171,"price":3.4,"value":581.4,"ownership":{"direct":false,"nature":"By Bios Fund I QP, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":207248,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111827,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-10","kind":"sale","planned":false,"acquired":false,"shares":3,"price":3.4,"value":10.2,"ownership":{"direct":false,"nature":"By Bios Fund I QP, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":207419,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1130645,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-29","kind":"sale","planned":false,"acquired":false,"shares":2199,"price":3.03,"value":6662.97,"ownership":{"direct":false,"nature":"By Bios Fund II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. On May 29, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $3.00 to $3.13 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":125332,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130644,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-28","kind":"sale","planned":false,"acquired":false,"shares":1632,"price":2.87,"value":4683.84,"ownership":{"direct":false,"nature":"By Bios Fund II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. On May 28, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $2.85 to $2.94 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":127531,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130643,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-27","kind":"sale","planned":false,"acquired":false,"shares":2290,"price":3.05,"value":6984.5,"ownership":{"direct":false,"nature":"By Bios Fund II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On May 27, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $2.87 to $3.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":129163,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130642,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-29","kind":"sale","planned":false,"acquired":false,"shares":7180,"price":3.03,"value":21755.4,"ownership":{"direct":false,"nature":"By Bios Fund II QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. On May 29, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $3.00 to $3.13 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":409296,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130641,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-28","kind":"sale","planned":false,"acquired":false,"shares":5332,"price":2.87,"value":15302.84,"ownership":{"direct":false,"nature":"By Bios Fund II QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. On May 28, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $2.85 to $2.94 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":416476,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130640,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-27","kind":"sale","planned":false,"acquired":false,"shares":7478,"price":3.05,"value":22807.9,"ownership":{"direct":false,"nature":"By Bios Fund II QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On May 27, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $2.87 to $3.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":421808,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130639,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-29","kind":"sale","planned":false,"acquired":false,"shares":961,"price":3.03,"value":2911.83,"ownership":{"direct":false,"nature":"By Bios Fund II NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. On May 29, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $3.00 to $3.13 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":54792,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130638,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-28","kind":"sale","planned":false,"acquired":false,"shares":714,"price":2.87,"value":2049.18,"ownership":{"direct":false,"nature":"By Bios Fund II NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. On May 28, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $2.85 to $2.94 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":55753,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130637,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-27","kind":"sale","planned":false,"acquired":false,"shares":1000,"price":3.05,"value":3050.0,"ownership":{"direct":false,"nature":"By Bios Fund II NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On May 27, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $2.87 to $3.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":56467,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130636,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-29","kind":"sale","planned":false,"acquired":false,"shares":6221,"price":3.03,"value":18849.63,"ownership":{"direct":false,"nature":"By Bios Fund I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. On May 29, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $3.00 to $3.13 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":354630,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130635,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-28","kind":"sale","planned":false,"acquired":false,"shares":4620,"price":2.87,"value":13259.4,"ownership":{"direct":false,"nature":"By Bios Fund I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. On May 28, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $2.85 to $2.94 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":360851,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130634,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-27","kind":"sale","planned":false,"acquired":false,"shares":6479,"price":3.05,"value":19760.95,"ownership":{"direct":false,"nature":"By Bios Fund I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On May 27, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $2.87 to $3.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":365471,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130633,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-29","kind":"sale","planned":false,"acquired":false,"shares":3639,"price":3.03,"value":11026.17,"ownership":{"direct":false,"nature":"By Bios Fund I QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. On May 29, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $3.00 to $3.13 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":207422,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130632,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-28","kind":"sale","planned":false,"acquired":false,"shares":2702,"price":2.87,"value":7754.74,"ownership":{"direct":false,"nature":"By Bios Fund I QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. On May 28, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $2.85 to $2.94 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":211061,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130631,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-27","kind":"sale","planned":false,"acquired":false,"shares":3790,"price":3.05,"value":11559.5,"ownership":{"direct":false,"nature":"By Bios Fund I QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On May 27, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $2.87 to $3.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":213763,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1156864,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":2,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":3,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":4,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":5,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":6,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":7,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":8,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":9,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":10,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrant","published_at":"2025-05-07T21:47:30.000Z","date":"2025-05-02","kind":"other","planned":false,"acquired":false,"shares":574241,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":1.5,"exercise_date":"2023-12-13","expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":574241},"source":{"system":"sec-edgar","filing":"0001104659-25-045738","document":"tm2514380-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465925045738/tm2514380-1_4seq1.xml","form_type":"4"}},{"id":1156863,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":2,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":3,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":4,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":5,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":6,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":7,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":8,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":9,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":10,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrant","published_at":"2025-05-07T21:47:30.000Z","date":"2025-05-02","kind":"other","planned":false,"acquired":false,"shares":574241,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":0.45,"exercise_date":"2023-12-13","expiration_date":"2025-10-04","underlying":"Common Stock","underlying_shares":574241},"source":{"system":"sec-edgar","filing":"0001104659-25-045738","document":"tm2514380-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465925045738/tm2514380-1_4seq1.xml","form_type":"4"}},{"id":1156862,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":2,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":3,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":4,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":5,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":6,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":7,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":8,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":9,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":10,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2025-05-07T21:47:30.000Z","date":"2025-05-02","kind":"purchase","planned":false,"acquired":true,"shares":1148482,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to a Warrant Exchange Agreement (the \"Warrant Exchange Agreement\"), dated as of April 26, 2025, between In8bio, Inc. (the \"Issuer\") and Bios Clinical Opportunity Fund, LP (\"Bios COF\"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the \"Pre-Funded Warrants\") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":2431763,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":1148482},"source":{"system":"sec-edgar","filing":"0001104659-25-045738","document":"tm2514380-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465925045738/tm2514380-1_4seq1.xml","form_type":"4"}},{"id":1387875,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":2,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":3,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":4,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":5,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":6,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":7,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":8,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":9,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":10,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrant","published_at":"2024-10-11T18:13:27.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":574241,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with the entry into the Purchase Agreement, the Series A warrants initially issued to Bios COF on December 13, 2023 were amended to reduce the exercise price of such warrants, which constitutes a cancellation of the old warrants and a grant of the new Series A warrants. In connection with such amendment, the termination date of such warrants was extended to October 4, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the entry into the Purchase Agreement, the Series A warrants initially issued to Bios COF on December 13, 2023 were amended to reduce the exercise price of such warrants, which constitutes a cancellation of the old warrants and a grant of the new Series A warrants. In connection with such amendment, the termination date of such warrants was extended to October 4, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":574241,"derivative":{"exercise_price":0.45,"exercise_date":"2023-12-13","expiration_date":"2025-10-04","underlying":"Common Stock","underlying_shares":574241},"source":{"system":"sec-edgar","filing":"0001104659-24-108140","document":"tm2425783-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924108140/tm2425783-3_4seq1.xml","form_type":"4"}},{"id":1387874,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":2,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":3,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":4,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":5,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":6,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":7,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":8,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":9,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":10,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrant","published_at":"2024-10-11T18:13:27.000Z","date":"2024-10-04","kind":"disposition_to_issuer","planned":false,"acquired":true,"shares":574241,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with the entry into the Purchase Agreement, the Series A warrants initially issued to Bios COF on December 13, 2023 were amended to reduce the exercise price of such warrants, which constitutes a cancellation of the old warrants and a grant of the new Series A warrants. In connection with such amendment, the termination date of such warrants was extended to October 4, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the entry into the Purchase Agreement, the Series A warrants initially issued to Bios COF on December 13, 2023 were amended to reduce the exercise price of such warrants, which constitutes a cancellation of the old warrants and a grant of the new Series A warrants. In connection with such amendment, the termination date of such warrants was extended to October 4, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":1.25,"exercise_date":"2023-12-13","expiration_date":"2025-06-13","underlying":"Common Stock","underlying_shares":574241},"source":{"system":"sec-edgar","filing":"0001104659-24-108140","document":"tm2425783-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924108140/tm2425783-3_4seq1.xml","form_type":"4"}},{"id":1387873,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":2,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":3,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":4,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":5,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":6,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":7,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":8,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":9,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":10,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Warrant","published_at":"2024-10-11T18:13:27.000Z","date":"2024-10-04","kind":"purchase","planned":false,"acquired":true,"shares":709040,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a Securities Purchase Agreement (the \"Purchase Agreement\"), dated as of September 30, 2024, between In8bio, Inc. (the \"Issuer\"), Bios Clinical Opportunity Fund, LP (\"Bios COF Fund\") and the Issuer, Bios COF purchased from the Issuer in a private placement 709,040 units at a price of $0.3949 per unit, each unit consisting of (i) one pre-funded warrant (the \"Pre-Funded Warrants\") to purchase one share of Common Stock and (ii) one Series C warrant (the \"Series C Warrants\") to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":709040,"derivative":{"exercise_price":0.27,"exercise_date":"2024-10-04","expiration_date":"2027-10-04","underlying":"Common Stock","underlying_shares":709040},"source":{"system":"sec-edgar","filing":"0001104659-24-108140","document":"tm2425783-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924108140/tm2425783-3_4seq1.xml","form_type":"4"}},{"id":1387872,"issuer":{"id":7941,"kind":"organization","name":"IN8BIO, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":2,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":3,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":4,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":5,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":6,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":7,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":8,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":9,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":10,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2024-10-11T18:13:27.000Z","date":"2024-10-04","kind":"purchase","planned":false,"acquired":true,"shares":709040,"ownership":{"direct":false,"nature":"By Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a Securities Purchase Agreement (the \"Purchase Agreement\"), dated as of September 30, 2024, between In8bio, Inc. (the \"Issuer\"), Bios Clinical Opportunity Fund, LP (\"Bios COF Fund\") and the Issuer, Bios COF purchased from the Issuer in a private placement 709,040 units at a price of $0.3949 per unit, each unit consisting of (i) one pre-funded warrant (the \"Pre-Funded Warrants\") to purchase one share of Common Stock and (ii) one Series C warrant (the \"Series C Warrants\") to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to a Securities Purchase Agreement (the \"Purchase Agreement\"), dated as of September 30, 2024, between In8bio, Inc. (the \"Issuer\"), Bios Clinical Opportunity Fund, LP (\"Bios COF Fund\") and the Issuer, Bios COF purchased from the Issuer in a private placement 709,040 units at a price of $0.3949 per unit, each unit consisting of (i) one pre-funded warrant (the \"Pre-Funded Warrants\") to purchase one share of Common Stock and (ii) one Series C warrant (the \"Series C Warrants\") to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to a Securities Purchase Agreement (the \"Purchase Agreement\"), dated as of September 30, 2024, between In8bio, Inc. (the \"Issuer\"), Bios Clinical Opportunity Fund, LP (\"Bios COF Fund\") and the Issuer, Bios COF purchased from the Issuer in a private placement 709,040 units at a price of $0.3949 per unit, each unit consisting of (i) one pre-funded warrant (the \"Pre-Funded Warrants\") to purchase one share of Common Stock and (ii) one Series C warrant (the \"Series C Warrants\") to purchase one share of Common Stock. The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":1283281,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":574241},"source":{"system":"sec-edgar","filing":"0001104659-24-108140","document":"tm2425783-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924108140/tm2425783-3_4seq1.xml","form_type":"4"}},{"id":1427778,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-20T20:45:30.000Z","date":"2024-08-14","kind":"sale","planned":false,"acquired":false,"shares":2324,"price":8,"value":18592.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 3,528 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 2,324 of the warrant shares to pay the exercise price and issuing to Bios Fund II NT the remaining 1,204 shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The original Form 4 filed on August 14, 2024 is being amended by this Form 4 amendment solely to correct the price reported in column 4 of Table I in the original Form 4, which inadvertently included the incorrect price. This amended report does not report any new transactions and all other information reported in the original Form 4 is correct."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":131248,"source":{"system":"sec-edgar","filing":"0001104659-24-091370","document":"tm2422197-3_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924091370/tm2422197-3_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-08-14"}},{"id":1427777,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-20T20:45:30.000Z","date":"2024-08-14","kind":"sale","planned":false,"acquired":false,"shares":17361,"price":8,"value":138888.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 26,355 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 17,361 of the warrant shares to pay the exercise price and issuing to Bios Fund II QP the remaining 8,994 shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The original Form 4 filed on August 14, 2024 is being amended by this Form 4 amendment solely to correct the price reported in column 4 of Table I in the original Form 4, which inadvertently included the incorrect price. This amended report does not report any new transactions and all other information reported in the original Form 4 is correct."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":980433,"source":{"system":"sec-edgar","filing":"0001104659-24-091370","document":"tm2422197-3_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924091370/tm2422197-3_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-08-14"}},{"id":1427776,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-20T20:45:30.000Z","date":"2024-08-14","kind":"sale","planned":false,"acquired":false,"shares":5314,"price":8,"value":42512.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 8,068 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 5,314 of the warrant shares to pay the exercise price and issuing to Bios Fund II the remaining 2,754 shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The original Form 4 filed on August 14, 2024 is being amended by this Form 4 amendment solely to correct the price reported in column 4 of Table I in the original Form 4, which inadvertently included the incorrect price. This amended report does not report any new transactions and all other information reported in the original Form 4 is correct."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":300143,"source":{"system":"sec-edgar","filing":"0001104659-24-091370","document":"tm2422197-3_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924091370/tm2422197-3_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-08-14"}},{"id":1433798,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-12","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Aaron G.L. Fletcher"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"The options vest and become exercisable on August 12, 2025, subject to the Mr. Fletcher's continuing service on the Issuer's Board of Directors through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":8,"expiration_date":"2034-08-12","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":56,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433797,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"other","planned":false,"acquired":false,"shares":3528,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 3,528 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 2,324 of the warrant shares to pay the exercise price and issuing to Bios Fund II NT the remaining 1,204 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F13","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 3,528 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 2,324 of the warrant shares to pay the exercise price and issuing to Bios Fund II NT the remaining 1,204 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"exercise_price":5.27,"underlying":"Common Stock","underlying_shares":3528},"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":55,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433796,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"other","planned":false,"acquired":false,"shares":26355,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 26,355 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 17,361 of the warrant shares to pay the exercise price and issuing to Bios Fund II QP the remaining 8,994 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 26,355 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 17,361 of the warrant shares to pay the exercise price and issuing to Bios Fund II QP the remaining 8,994 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"exercise_price":5.27,"underlying":"Common Stock","underlying_shares":26355},"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":54,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433795,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"other","planned":false,"acquired":false,"shares":8068,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 8,068 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 5,314 of the warrant shares to pay the exercise price and issuing to Bios Fund II the remaining 2,754 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 8,068 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 5,314 of the warrant shares to pay the exercise price and issuing to Bios Fund II the remaining 2,754 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"exercise_price":5.27,"underlying":"Common Stock","underlying_shares":8068},"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":53,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433794,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":573394,"ownership":{"direct":false,"nature":"Directly held by Bios Actuate Co-Invest III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":573394},"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":52,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433793,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":78267,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III NT, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":78267},"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":51,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433792,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":484638,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III QP, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":484638},"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":50,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433791,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":74202,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":74202},"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":49,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433790,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-4 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":2094650,"ownership":{"direct":false,"nature":"Directly held by Bios Actuate Co-Invest II, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2094650},"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":48,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433789,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-4 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":326547,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III NT, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":326547},"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":47,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433788,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-4 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":2022029,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III QP, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2022029},"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":46,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433787,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-4 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":309589,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":309589},"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":45,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433786,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-3 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":44559,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":44559},"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":44,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433785,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-3 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":332867,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":332867},"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":43,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433784,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-3 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":101900,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":101900},"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":42,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433783,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":147047,"ownership":{"direct":false,"nature":"Directly held by Bios Actuate Co-Invest I, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":147047},"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":41,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433782,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":23628,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":23628},"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":40,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433781,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":176499,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":176499},"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":39,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433780,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":54032,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":54032},"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":38,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433779,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":153702,"ownership":{"direct":false,"nature":"Directly held by Bios Actuate Co-Invest I, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":153702},"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":37,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433778,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":61857,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":61857},"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":36,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433777,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":462073,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":462073},"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":35,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433776,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":141457,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":141457},"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":34,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433775,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":307538,"ownership":{"direct":false,"nature":"Directly held by Bios Fund I QP, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of Series A Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of Series A Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of Series A Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of Series A Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":307538},"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":33,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433774,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":525797,"ownership":{"direct":false,"nature":"Directly held by Bios Fund I, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of Series A Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of Series A Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of Series A Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of Series A Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":525797},"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":32,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433773,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Note","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":884427,"ownership":{"direct":false,"nature":"Directly held by Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects a convertible note that was convertible into shares of common stock of the Issuer. The principal amount of the convertible note together with accrued interest was automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to the initial offering price multiplied by 0.8."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a convertible note that was convertible into shares of common stock of the Issuer. The principal amount of the convertible note together with accrued interest was automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to the initial offering price multiplied by 0.8."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects a convertible note that was convertible into shares of common stock of the Issuer. The principal amount of the convertible note together with accrued interest was automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to the initial offering price multiplied by 0.8."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects a convertible note that was convertible into shares of common stock of the Issuer. The principal amount of the convertible note together with accrued interest was automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to the initial offering price multiplied by 0.8."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reflects a convertible note that was convertible into shares of common stock of the Issuer. The principal amount of the convertible note together with accrued interest was automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to the initial offering price multiplied by 0.8."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":884427},"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":31,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433772,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"sale","planned":false,"acquired":false,"shares":2324,"price":9,"value":20916.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F13","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 3,528 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 2,324 of the warrant shares to pay the exercise price and issuing to Bios Fund II NT the remaining 1,204 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":131248,"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433771,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"other","planned":false,"acquired":true,"shares":3528,"price":5.27,"value":18592.56,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":133572,"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433770,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"sale","planned":false,"acquired":false,"shares":17361,"price":9,"value":156249.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F12","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 26,355 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 17,361 of the warrant shares to pay the exercise price and issuing to Bios Fund II QP the remaining 8,994 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":980433,"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433769,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"other","planned":false,"acquired":true,"shares":26355,"price":5.27,"value":138890.85,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":997794,"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433768,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"sale","planned":false,"acquired":false,"shares":5314,"price":9,"value":47826.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 8,068 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 5,314 of the warrant shares to pay the exercise price and issuing to Bios Fund II the remaining 2,754 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":300143,"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433767,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"other","planned":false,"acquired":true,"shares":8068,"price":5.27,"value":42518.36,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":305457,"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433766,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":573394,"ownership":{"direct":false,"nature":"Directly held by Bios Actuate Co-Invest III, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":573394,"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433765,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":78267,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":404814,"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433764,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":484638,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":2506667,"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433763,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":74202,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":383791,"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433762,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":2094650,"ownership":{"direct":false,"nature":"Directly held by Bios Actuate Co-Invest II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":2094650,"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433761,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":326547,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":326547,"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433760,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":2022029,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":2022029,"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433759,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":309589,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":309589,"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433758,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":44559,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":130044,"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433757,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":332867,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":971439,"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433756,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":101900,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":297389,"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433755,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":147047,"ownership":{"direct":false,"nature":"Directly held by Bios Actuate Co-Invest I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":300749,"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433754,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":23628,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":85485,"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433753,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":176499,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":638572,"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433752,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":54032,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":195489,"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433751,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":153702,"ownership":{"direct":false,"nature":"Directly held by Bios Actuate Co-Invest I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":153702,"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433750,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":61857,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":61857,"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433749,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":462073,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":462073,"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}},{"id":1433748,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:44:04.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":141457,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":141457,"source":{"system":"sec-edgar","filing":"0001104659-24-089819","document":"tm2421559-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465924089819/tm2421559-12_4seq1.xml","form_type":"4"}}],"next_cursor":"2024-08-14T20:44:04.000000Z,1433748"}